Postmarketing commitments for novel drugs and biologics approved by the US Food and Drug Administration: a cross-sectional analysis

被引：0
|
作者：
Joshua D. Wallach
Anita T. Luxkaranayagam
Sanket S. Dhruva
Jennifer E. Miller
Joseph S. Ross
机构：
[1] Yale School of Public Health,Department of Environmental Health Sciences
[2] Yale Law School,Collaboration for Research Integrity and Transparency (CRIT)
[3] Center for Outcomes Research and Evaluation (CORE),Department of Medicine
[4] Yale-New Haven Hospital,Section of General Medicine, Department of Internal Medicine
[5] University of Connecticut,National Clinician Scholars Program, Department of Internal Medicine
[6] University of California,Department of Health Policy and Management
[7] San Francisco School of Medicine,undefined
[8] Section of Cardiology,undefined
[9] San Francisco Veterans Affairs Health Care System,undefined
[10] Yale School of Medicine,undefined
[11] Yale School of Medicine,undefined
[12] Yale School of Public Health,undefined
来源：
BMC Medicine | / 17卷
关键词：
Postmarketing commitments; Postmarketing requirements; FDA; Lifecycle evaluation; Pharmaceutical regulation;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Clinical benefit and cost of breakthrough cancer drugs approved by the US Food and Drug Administration
    Molto, Consolacion
    Hwang, Thomas J.
    Borrell, Maria
    Andres, Marta
    Gich, Ignasi
    Barnadas, Agusti
    Amir, Eitan
    Kesselheim, Aaron S.
    Tibau, Ariadna
    CANCER, 2020, 126 (19) : 4390 - 4399
  • [42] Mechanisms of Action of the US Food and Drug Administration-Approved Antisense Oligonucleotide Drugs
    Sang, Angela
    Zhuo, Selena
    Bochanis, Adara
    Manautou, Jose E.
    Bahal, Raman
    Zhong, Xiao-bo
    Rasmussen, Theodore P.
    BIODRUGS, 2024, 38 (04) : 511 - 526
  • [43] Correction to: A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2021
    Gizem Kayki-Mutlu
    Zinnet Sevval Aksoyalp
    Leszek Wojnowski
    Martin C. Michel
    Naunyn-Schmiedeberg's Archives of Pharmacology, 2023, 396 : 383 - 383
  • [44] RE: Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration
    Cherny, Nathan I.
    Dafni, Urani
    Bogaerts, Jan
    Latino, Nicola J.
    Pentheroudakis, George
    Douillard, Jean-Yves
    Tabernero, Josep
    Zielinski, Christoph
    Piccart, Martine J.
    de Vries, Elisabeth G. E.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2018, 110 (10):
  • [45] A Survey of Survival Outcomes for Targeted Cancer Drugs Approved by the US Food and Drug Administration
    He, Qian
    Li, Qiu
    Lv, Fanzhen
    Kaitin, Kenneth I.
    Shao, Liming
    THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2021, 55 (04) : 676 - 684
  • [46] A Survey of Survival Outcomes for Targeted Cancer Drugs Approved by the US Food and Drug Administration
    Qian He
    Qiu Li
    Fanzhen Lv
    Kenneth I. Kaitin
    Liming Shao
    Therapeutic Innovation & Regulatory Science, 2021, 55 : 676 - 684
  • [47] Power Morcellators, Postmarketing Surveillance, and the US Food and Drug Administration
    Redberg, Rita F.
    Jacoby, Alison F.
    Sharfstein, Joshua M.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2017, 318 (04): : 325 - 326
  • [48] DRUGS APPROVED FOR CLINICAL USE BY FOOD AND DRUG ADMINISTRATION
    DEHAEN, P
    JOURNAL OF NEW DRUGS, 1965, 5 (06): : 358 - &
  • [49] DRUGS APPROVED FOR CLINICAL USE BY FOOD AND DRUG ADMINISTRATION
    DEHAEN, P
    JOURNAL OF NEW DRUGS, 1966, 6 (02): : 112 - &
  • [50] Role of US military research programs in the development of US Food and Drug Administration - Approved antimalarial drugs
    Kitchen, LW
    Vaughn, DW
    Skillman, DR
    CLINICAL INFECTIOUS DISEASES, 2006, 43 (01) : 67 - 71
12345